Drug-Coated Chocolate PTA Balloon in Patients With Peripheral Arterial Disease - The ENDURE Trial

Not Applicable

Completed

• Conditions: Peripheral Vascular Disease
• Interventions: Device: Paclitaxel Coated Chocolate Balloon Angioplasty

• Registration Number: NCT02129127
• Lead Sponsor: TriReme Medical, LLC

Brief Summary

This first-in-man study is to evaluate the Drug-Coated Chocolate (DCC) Balloon for percutaneous arterial angioplasty in patients with symptomatic peripheral arterial disease. The study focuses on acute device performance and peri-procedural safety and also seeks to further characterize the performance of the device.

Detailed Description

This is a prospective, multi-center, single-arm study. Symptomatic lower extremity Peripheral Arterial Disease (PAD) patients presenting for endovascular revascularization will be enrolled in the study if they meet all entry criteria. The study will include patients from New Zealand and the European Union. The endpoints were designed to establish safety of the DCC and to identify long-term clinical benefits of this technology.

The patients treated in this study will be designated into the above the knee (ATK) follow-up schedule if they are treated with the DCC in the SFA or Popliteal vessels. This schedule calls for clinical visits with duplex ultrasounds at 1,6 and 12 months. Patients will be designated into the below the knee (BTK) follow-up schedule if they are treated with the DCC in the Peroneal, Anterior Tibial, Posterior Tibial or Pedal vessels. These patients will have clinical visits at 1, 3 and 6 months with duplex ultrasound at the 1 and 6 months visits only.

Study Timeline

• Study Start: 2014-03
• Study First Submitted: 2014-04-30
• Study First Submitted QC: 2014-04-30
• Study First Posted: 2014-05-02
• Primary Completion: 2015-06
• Status Verified: 2017-04
• Study Completion: 2017-04
• Last Update Submitted: 2017-04-12
• Last Update Posted: 2017-04-14

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 67

Inclusion Criteria

• Intermittent claudication or critical limb ischemia
• Atherosclerotic target lesion >70% stenosis
• Reference vessel diameter (RVD) between 2.0 and 6.0mm
• Angiographic evidence of distal run-off
• Target lesion length <150mm that consists of no more than two adjacent lesions( < 25mm apart) and is able to be completely covered with inflation of no more than two DCC devices

Key

Exclusion Criteria

• Acute limb ischemia or thrombolytic therapy
• Known and relevant allergies/hypersensitivities
• Known impaired renal function
• Known bleeding disorder
• Severe calcification at the target lesion
• Previous bypass or stent at, or proximal to, target vessel
• Aneurysm in target limb
• Prior major limb amputation
• Use of a any of the following: re-entry device, atherectomy, laser or other ablation procedure, or cutting/scoring balloon at the target lesion; use of drug eluting stent, or non-study drug coated balloon in the target limb.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Drug Coated Chocolate	Paclitaxel Coated Chocolate Balloon Angioplasty	Paclitaxel Coated Chocolate Balloon Angioplasty

Primary Outcome Measures

Name	Time	Method
Late Lumen Loss (LLL)	3 Months (BTK) or 6 Months (ATK)	LLL is determined by assessing the difference between the minimum lumen diameter (MLD) immediately after treatment with the DCC and the MLD at angiographic follow-up. LLL will determined by the Angiographic Core Laboratory.

Secondary Outcome Measures

Name	Time	Method
Device Success	approx 1 hour	This is defined as the percentage of procedures that accomplish less than 30% residual stenosis without flow-limiting dissection at target lesion after DCC treatment.
Device Related Adverse Events (AEs)	30 days	Occurrence and Severity of any DCC Related AEs will be analyzed
Technical Success	approx 1 hour	This is defined as the percentage of cases in which the DCC is able to be delivered to and inflated at the intended target lesion location successfully.
Freedom from Target Lesion Revascularization (TLR)	30 days / 3 Months (BTK only) / 6 Months / 12 Months (ATK only)	This will calculate the number of patients who do not require a clinically indicated TLR. Clinically indicated TLR is defined as any repeat percutaneous intervention at the DCC target lesion or bypass surgery at the DCC target vessel performed for \>50% restenosis or another complication of the target lesion
Amputation Free Survival	30 days / 3 Months (BTK only) / 6 Months / 12 Months (ATK only)	This is a composite endpoint which counts the number of patients who experience limb salvage. Patients will fail this endpoint if they undergo a major amputation (defined as unplanned amputation at or above the ankle) or if a procedure related death occurs.
Patency	6 Months / 12 Months (ATK only)	The percentage of cases in which the treated lesion is patent. Patency is demonstrated by a Peak Systolic Velocity ratio \<2.5 at the target lesion assessed on Duplex Ultrasound without the need for re-intervention.

Trial Locations

Locations (2)

Auckland City Hospital; 🇳🇿 Auckland, New Zealand

Universitats Herzzentrum Bad Krozingen; 🇩🇪 Bad Krozingen, Germany